Literature DB >> 28990250

Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity.

S F Issa1, A F Christensen2, H M Lindegaard1, M L Hetland3,4, K Hørslev-Petersen5, K Stengaard-Pedersen6, B J Ejbjerg7, T Lottenburger2, T Ellingsen1, J K Pedersen1, K Junker8, A Svendsen9, U Tarp6, M Østergaard3,4, P Junker1.   

Abstract

Galectin-3 has been suggested as a pro-inflammatory mediator in animal arthritis and rheumatoid arthritis (RA). We aimed to study the serum level of galectin-3 in patients with newly diagnosed RA and associations with disease profile, Magnetic resonance imaging (MRI) findings and seromarkers of synovial matrix inflammation. One hundred and sixty DMARD naïve patients newly diagnosed with RA were included (CIMESTRA study). Clinical, serological and imaging data were recorded before treatment and at 6 weeks, 3 and 12 months. Galectin-3 and hyaluronan (HYA) were measured by ELISA (R&D and Corgenix, USA), and the N-terminal propeptide of type III collagen (PIIINP) by radioimmunoassay (Orion Diagnostica, Finland). One hundred and nineteen, 87 and 60 blood donors served as controls for galectin-3, HYA and PIIINP, respectively. Baseline galectin-3 was significantly elevated in anti-CCP positive (4.2 μg/l IQR [3.6;6.1]) patients as compared with anti-CCP negatives (4.0 μg/l [2.6;4.9], P = 0.05) and controls (3.8 μg/l [3.0;4.8], P < 0.01). During treatment, galectin-3 remained elevated, but increased transiently with peak values at 6 weeks. Galectin-3 correlated with baseline smoking, anti-CCP, and with MRI erosion score after 1 year of follow-up. HYA and PIIINP were elevated (P < 0.001) irrespective of anti-CCP status and correlated positively with synovitis assessed clinically and by MRI. HYA and PIIINP did not correlate with galectin-3. These observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.
© 2017 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28990250     DOI: 10.1111/sji.12619

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis.

Authors:  Panagiota Anyfanti; Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Panagiotis Dolgyras; Vasiliki Galanopoulou; Spyros Aslanidis; Stella Douma
Journal:  Clin Cardiol       Date:  2018-11-27       Impact factor: 2.882

2.  Galectins-1 and-3 Increase in Equine Post-traumatic Osteoarthritis.

Authors:  Heidi L Reesink; Alan J Nixon; Jin Su; Sherry Liu; Ryan M Sutton; Sabine Mann; Ashlee E Watts; Ryan P Peterson
Journal:  Front Vet Sci       Date:  2018-11-20

Review 3.  Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases.

Authors:  Akira Hara; Masayuki Niwa; Kei Noguchi; Tomohiro Kanayama; Ayumi Niwa; Mikiko Matsuo; Yuichiro Hatano; Hiroyuki Tomita
Journal:  Biomolecules       Date:  2020-03-03

Review 4.  Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.

Authors:  Jianmin Chen; Lucy V Norling; Dianne Cooper
Journal:  Cells       Date:  2021-04-13       Impact factor: 6.600

Review 5.  Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity.

Authors:  Santiago P Mendez-Huergo; Pablo F Hockl; Juan C Stupirski; Sebastián M Maller; Luciano G Morosi; Nicolás A Pinto; Ana M Berón; Jorge L Musuruana; Gustavo G Nasswetter; Javier A Cavallasca; Gabriel A Rabinovich
Journal:  Front Immunol       Date:  2019-01-09       Impact factor: 7.561

6.  Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients.

Authors:  Yuya Fujita; Tomoyuki Asano; Naoki Matsuoka; Jumpei Temmoku; Shuzo Sato; Haruki Matsumoto; Makiko Yashiro Furuya; Eiji Suzuki; Hiroshi Watanabe; Atsushi Kawakami; Kiyoshi Migita
Journal:  Arthritis Res Ther       Date:  2020-04-15       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.